EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Paraproteinemic neuropathies

Rebecca Traub iD, Taha Qarni, Adam D Cohen, Chafic Karam iD

Muscle & Nerve · 2024-08 · 70 (2) · 173-179

DOI: 10.1002/mus.28164 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Muscle & Nerve, online erschienen am 30.05.2024. Verfasst von Rebecca Traub und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Paraproteinemias, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The diagnostic evaluation of a peripheral neuropathy includes testing for the presence of monoclonal gammopathy, which can be found in about 10% of patients with peripheral neuropathy. Our role, as physicians, is to determine whether the neuropathy is directly related to the gammopathy or whether the co‐occurrence of these two disorders is purely coincidental. The evaluating physician needs to be familiar with the different types of neuropathies associated with monoclonal gammopathies, their clinical and electrodiagnostic characteristics, and their appropriate diagnostic evaluation and management. Testing for monoclonal protein disorders includes serum protein electrophoresis (SPEP) and immunofixation of blood, and in some cases of urine, as well as measurement of free light chains and quantitative immunoglobulins. Specific antibody testing is directed by paraprotein type and neuropathy phenotype. Patients with abnormal free light chains in association with sensory and autonomic neuropathy should be evaluated for AL amyloidosis. When a lambda monoclonal protein is identified together with a clinical phenotype of chronic inflammatory demyelinating neuropathy (CIDP), a diagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS) syndrome should be considered. Patients with IgM paraprotein associated neuropathy should be assessed for distal acquired demyelinating sensorimotor (DADS) neuropathy, with or without anti myelin associated glycoprotein (MAG) antibody or CANOMAD syndrome. In many cases, a monoclonal gammopathy of uncertain significance (MGUS) is incidental and unrelated to the neuropathy. Collaboration with oncology is critical in evaluating patients with monoclonal proteins to assess for underlying plasma cell neoplasms or B cell lymphomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParaproteinemiasPeripheral Nervous System DiseasesHumans

Stichwörter der Autor:innen

CANOMADMGUSPOEMS syndromeamyloidneuropathyparaproteinemic neuropathy

Autor:innen und Institutionen

  • Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Amyloidosis Program, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Rebecca Traub, Chafic Karam

Zitieren

APA

Traub, R., Qarni, T., Cohen, A. D., & Karam, C. (2024). Paraproteinemic neuropathies. Muscle & Nerve, 70(2), 173-179. https://doi.org/10.1002/mus.28164

Vancouver

Traub R, Qarni T, Cohen AD, Karam C. Paraproteinemic neuropathies. Muscle & Nerve. 2024;70(2):173-179. doi:10.1002/mus.28164

BibTeX
@article{Traub2024,
  author = {Traub, Rebecca and Qarni, Taha and Cohen, Adam D and Karam, Chafic},
  title = {Paraproteinemic neuropathies},
  journal = {Muscle & Nerve},
  year = {2024},
  volume = {70},
  number = {2},
  pages = {173--179},
  doi = {10.1002/mus.28164}
}
Kostenlos starten →